Trastuzumab-deBouganin conjugate overcomes multiple mechanisms of T-DM1 drug resistance
RL Dillon, S Chooniedass, A Premsukh… - Journal of …, 2016 - journals.lww.com
The development of antibody drug conjugates has provided enhanced potency to tumor-
targeting antibodies by the addition of highly potent payloads. In the case of trastuzumab-
DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of
mertansine (DM1) to trastuzumab substantially increased progression-free survival. Despite
these improvements, most patients eventually relapse due to complex mechanisms of
resistance often associated with small molecule chemotherapeutics. Therefore, identifying …
targeting antibodies by the addition of highly potent payloads. In the case of trastuzumab-
DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of
mertansine (DM1) to trastuzumab substantially increased progression-free survival. Despite
these improvements, most patients eventually relapse due to complex mechanisms of
resistance often associated with small molecule chemotherapeutics. Therefore, identifying …